Compare Adaptive Biotechnologies Corp (ADPT) vs Kroger Co (KR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Kroger Co — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while Kroger Co trades at $59.04 (market cap $35.86B). The key difference: Kroger Co is far larger — about 10.8× Adaptive Biotechnologies Corp's market cap, and Kroger Co pays a 2.46% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KR | |
|---|---|---|
Market Cap | $3.33B | $35.86B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $75.60 |
52-Week Low | $10.24 | $55.53 |
Enterprise Value | $3.19B | $55.96B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Kroger (KR) trades at $58.54, up 0.55% today, with a bearish technical signal but strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. The company announced a $1.65 billion acquisition of Giant Eagle, expanding its Midwest footprint. Cash flow improved in 2025 with net cash flow of $2.08 billion, though net income margin remains thin at 0.71%.
Outlook is cautiously optimistic with a $67.29 price target, but risks include competitive pressures and rising debt. The stock offers growth through strategic acquisitions and dividend hikes, yet faces margin compression and integration challenges from recent deals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
